ロード中...
High Prevalence and Conservative Management of Acute Cholecystitis during Lenvatinib for Advanced Thyroid Cancer
INTRODUCTION: Lenvatinib (LEN) is a multitarget tyrosine kinase inhibitor currently used for advanced, radioiodine refractory differentiated thyroid cancer (RAI-R DTC). Among adverse events (AEs), nausea, vomiting, and decreased appetite have been frequently described. We aimed to evaluate the preva...
保存先:
| 出版年: | Eur Thyroid J |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
S. Karger AG
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8314780/ https://ncbi.nlm.nih.gov/pubmed/34395303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000510369 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|